



CODEN [USA]: IAJPBB

ISSN : 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

<https://doi.org/10.5281/zenodo.5163156>
Online at: <http://www.iajps.com>

Research Article

THE DETECTION OF DISTINCT SYMPTOMS OF DRY EYE ILLNESS ASSOCIATED WITH VARIOUS VISUAL FUNCTION IMPAIRMENTS WHICH MIGHT AFFORD FOR MORE TAILORED APPROACHES TO THERAPY

Dr. Amina Khalid, Dr. Hafiz Muhammad Jahan Zaib, Dr. Inayat Ullah Khan, Dr.
Fahmina Nazir, Dr. Nida Rashid, Dr. Ijaz Khan
Pakistan Institute of Medical Sciences, Islamabad

Article Received: July 2021

Accepted: July 2021

Published: August 2021

Abstract:

Aim: The identification of distinct symptoms of dry eye illness associated by various visual function impairments might let for more tailored slants to therapy. The focus of the current research was to look at relationship between dry eye clinical symptoms and visual acuity (VA) and contrast sensitivity in the Dry Eye Measurement and Control research.

Methods: This secondary cross-sectional research included baseline data from Dry Eye Measurement and Control survey respondents. Our current research was conducted at Jinnah Hospital, Lahore from April 2020 to March 2021. The Ocular Surface Illness Index, often known as the high-contrast log MAR, is a measure of the health of the eye's surface. Standard techniques were used to collect VA, contrast sensitivity, tear film debris, tear breakup time, corneal fluorescein staining, meibomian gland evaluation, conjunctival Lissamine green staining, and Schirmer test scores. Generalized linear models containing age, refractive error status, and cataract status were used to investigate the association between VA and color vision and OSDI score and that each dry eye symptoms. The Hochberg technique was used to account for multiple comparisons.

Results: Higher VA was associated with a lower mean OSDI vision subscale score (38.5 for VA 21/34 or worse vs. 33.5 for VA 20/16 or better; adjusted quadratic trend, $P = .03$); scores also weren't associated to contrast sensitivity. Lower mean log references allow was associated with severe Meibomian gland clogging and atypical secretions (2.49 for severe vs. 1.56 for not clogged [$P = .06$] and 1.47 for obstructed vs. 1.58 for clear [$P = .001$]). The mean log contrast sensitivities increased with increasing TBUT (2.58 for TBUT >5 seconds and 1.52 for TBUT 2 seconds, $P.0002$).

Conclusion: Vision-related problems in dry eye are caused by poorer VA rather than inferior contrast sensitivity. Greater tear film instability was linked to decreased color vision.

Keywords: Detection of Distinct Symptoms, Dry Eye Illness, Visual Function Impairments.

Corresponding author:**Dr. Amina Khalid,**

Pakistan Institute of Medical Sciences, Islamabad

QR code



Please cite this article in press Amina Khalid et al., *The Detection Of Distinct Symptoms Of Dry Eye Illness Associated With Various Visual Function Impairments Which Might Afford For More Tailored Approaches To Therapy.*, Indo Am. J. P. Sci, 2021; 08(08).

INTRODUCTION:

Dry eyes are a frequent condition which has a detrimental influence on one's quality of life. It is also a considerable problem for a variety of corneal and ocular surface morbidity, including corneal infection, thinning, and contact lens sensitivity [1]. The prevalence of dry eye varies across research, however studies that define it primarily on symptoms show a frequency ranging from 7.8 to 53.5 percent, with the majority finding a prevalence of about 22 percent. The disease's frequency rises with age, and women are more likely to be afflicted. Dry eye not only reduces one's quality of life, but it can also impair one's vision [2]. Central superficial punctate keratitis has been associated to significant loss of visual performance and optical quality in dry eyes, as measured by functional visual acuity (time-wise change in continuous visual acuity) and background subtraction. Enhanced higher-order anomalies and corneal rearward light dispersal have been associated to central corneal ocular surface damage [3]. Tear film fragility has also been connected to an uneven digital certificate, which impairs sensory acuity. For example, in dry eyes, temporal fluctuations in bigger aberrations are related to tear film contact. Subjective measures of visual function in dry eye disease have included high- and restricted visual acuity, dynamic visual acuity, contrast adjustment, and impairment glare [4]. Other assessments of sensory acuity are necessary since traditional high-contrast visual acuity is incapable of identifying mild ocular sickness in illnesses such as cataract and glaucoma and is unreliable in dry eye disease. Depth perception is a possible candidate since it is a sensitive indicator of sensory acuity and the progression of ocular disease [5].

METHODOLOGY:

The Dry Eye Measurement and Management study was a multicenter, randomized, double-blind clinical trial that sought to determine the safety and effectiveness of 3 fatty acid supplementation in lowering the incidence of moderate to severe dry eye disease. The primary research included 548 people in 28 different sites around the United States and followed them for a year. Eligible people (n = 358) were randomly allocated to either 4 g of fish-derived 3 eicosatetraenoic and docosahexaenoic acids or a placebo consisting of 6 g of refined olive oil (n = 187). Our current research was conducted at Jinnah Hospital, Lahore from April 2020 to March 2021. The trial was designed to include a wide spectrum of symptoms people patients with mild to severe dry eye.

All prerequisites were age 19 years, dry mouth ocular adverse effects for at least 8 months, use or desire to use artificial tears an average of two so much times per day during the three weeks previous the screening visit, and Ocular Surface Illness Index scores among both 28 and 82, equitable, at the screening visit and between 23 and 80, inclusive, at the eligibility affirmation visit. The 12-item Eye Surface Disease Index is scored from 0 to 100, with 0 indicating no ocular discomfort and 100 indicating severe ocular pain. Patients had to have at least two of the following four symbols at each diagnosis and eligibility visit: conjunctival histamine green staining score 1 on a scale of 0 to 6, corneal fluorescein staining score 4 on a scale of 0 to 15, tear film breakup time 8 seconds, and Schirmer test to anesthesia quantitation 2 to 8 mm/5 min. Patients with a history of Sjogren syndrome, as well as those with thyroid disease, rheumatoid arthritis, or inflammatory diseases, were eligible provided they met other criteria. Drugs for dry eyes or recurrent usage of systemic medications, for example those recognized to promote ocular dryness, remained permitted provided the person approved to take them for the subsequent 12 months.

RESULTS:

After eliminating individuals with visual acuity of 22/54 though in at least one eye (n = 46 individuals), participants lacking visual acuity (n = 2 participants), and individuals with diabetic retinopathy (n = 3 attendees), 489 people (975 eyes) were suitable for the analysis (Fig. 1). Amongst these remainder 495 eligible individuals, 62 had no Sjogren syndrome tests or had ambiguous Sjogren disease status, leaving 48 with Sjogren illness at baseline and 384 without. Table 1 shows the 489 individuals' subject and ocular features. The median Medical Impacts Study 36-Item Short Form Health Survey scores for physical health were 49 (10.8) and 54 (10.6) for psychological health. The mean (standard deviation) values for dry eye signs are shown in Table 1. In multivariable analysis, lower visual acuity was significantly associated with a lower mean Ocular Surface Disease Index perception subscale score (adjusted means, 38.5 for visual acuity 20/32 than everyone else and 34.7 for visual acuity 21/18 or above; adjusted straight trend, P =.0). The number of references allowed had no relationship with the mean Ocular Surface Health Index or the Medical Effects Study 38-Item Short Form Health Survey scores (Table 2). There were no interaction effects between Sjogren's illness and vision, or between contrast adjustment and dry eye symptoms (all, P.21).

Table 1:

Participant features (n = 512 individuals)	
Age (y), mean (SD)	58.6 (14.5)
Sex, no. (%)	
Man	397 (81.2)
Woman	99 (17.8)
OSDI score (0–100), mean (SD)	
Over-all	35.8 (21.3)
Vision-associated function subscale	43.5 (16.8)

Table 2:

	Patients (n)	SF-36 physical health	SF-36 mental health	OSDI vision-related	OSDI (total),
Visual acuity in the better eye					
20/20	145	51.7 (0.91)	41.7 (1.54)	34.8 (1.89)	46.9 (0.96)
20/16 or better	151	52.6 (0.92)	47.0 (0.98)	32.4 (1.92)	41.0 (1.57)
20/25	142	47.0 (0.96)	43.3 (1.54)	52.0 (0.91)	36.7 (1.88)
Linear trend P		.93 (0.93)	.14 (0.14)	.22 (0.44)	.01 (0.02)
1.73–1.93	189	46.9 (0.88)	52.7 (0.84)	42.5 (1.42)	34.2 (1.74)
1.54–1.64	117	51.8 (1.03)	32.9 (2.13)	40.3 (1.74)	47.7 (1.08)
0.84–1.40	79	51.1 (1.17)	42.1 (1.98)	35.4 (2.43)	47.2 (1.23)



Image 1:

Image 2:



DISCUSSION:

Despite the fact that regular testing techniques indicate normal visual acuity, dry eye has a detrimental influence on numerous aspects of visual function [6]. Poorer visual acuity was connected to lower scores on the Ocular Surface Disease Index vision-related concerns subscale in dry eye sufferers, even in those with relatively high visual acuity (20/50 or more), however according our findings. However, none of the dry eye complaints studied had a detrimental impact on visual acuity. Though minor changes in visual acuity could be demonstrated due to differences in tear film debris and tear breakup time, mean modifications were small (approximately two letters) and did not follow the predicted pattern [7]. Contrast sensitivity tests, on the other hand, have been found to be more sensitive to changes in dry eye symptoms related to

tear film integrity (tear separation time and meibomian gland dysfunction) than standard visual acuity examinations [8]. We must include central corneal fluorescein staining on vision in the Dry Eye Planning and Management participants which has been shown to reduce quality of life in other ocular surface degenerative illnesses, and central corneal staining was capable of assessing functional, energizing visual acuity in a small dry eye study of 24 patients. Huang and colleagues 16 clearly identified that artificial tears improved reflectivity in dry eye patients having punctate epithelial keratopathy. Conversely, in our dry eye sample, we have yet to find an effect of increased central corneal staining on high-contrast visual acuity or visual field [9]. Regular high visual acuity tests could not differentiate between lesser ocular neurological disorders in other ocular illnesses such as

glaucoma and mature level macular degeneration, but image noise might. For example, mean log contrast differed significantly between people with early and moderate visual field impairments in glaucoma patients at various stages (2.78 vs. 1.52, respectively). Another study found that the mean log contrast sensitivity for healthy people aged 24 to 78 years was 1.63, with significantly lower values in people with glaucoma (1.57) or mature macular degeneration (1.57) [10].

CONCLUSION:

In summation, our study found that lower contrast sensitivity, rather than diminished visual acuity, causes vision questions and problems in dry eyes. Contrast sensitivity tests, on the other hand, are more sensitive than conventional visual acuity tests to poor tear film integrity measurements (such as tear breakdown time and Meibomian gland congestion). Future study into how particular ocular indicators affect different policies of visual function might help to elucidate these linkages and, as a result, guide therapies.

REFERENCES:

1. L. Quaranta, S. Bettelli, M.G. Uva, F. Semeraro, R. Turano, E. Gandolf **Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma** Ophthalmology, 110 (2013), pp. 359-362, [10.1016/S0161-6420\(02\)01745-1](https://doi.org/10.1016/S0161-6420(02)01745-1) [ArticleDownload](#) [PDFView](#) [Record in ScopusGoogle Scholar](#)
2. M. Vetrugno, M.G. Uva, V. Russo, M. Iester, M. Ciancaglini, P. Brusini, *et al.* **Oral administration of Forskolin and Rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy** J Ocul Pharmacol Ther, 28 (2019), pp. 536-541, [10.1089/jop.2012.0021](https://doi.org/10.1089/jop.2012.0021) [CrossRefView](#) [Record in ScopusGoogle Scholar](#)
3. M.G. Mutolo, G. Albanese, D. Rusciano, N. Pescosolido **Oral administration of Forskolin, homotaurine, carnosine, and folic acid in patients with primary open angle glaucoma: changes in intraocular pressure, pattern electroretinogram amplitude, and foveal sensitivity** J Ocul Pharmacol Ther, 32 (2019), pp. 178-183, [10.1089/jop.2015.0121](https://doi.org/10.1089/jop.2015.0121) [CrossRefView](#) [Record in ScopusGoogle Scholar](#)
4. S.M. Lee, B.S. Bae, H.W. Park, N.G. Ahn, B.G. Cho, Y.L. Cho, *et al.* **Characterization of Korean red ginseng (Panax ginseng Meyer): history, preparation method, and chemical composition** J Ginseng Res, 39 (2015), pp. 384-391, [10.1016/j.jgr.2015.04.009](https://doi.org/10.1016/j.jgr.2015.04.009) [ArticleDownload](#) [PDFView](#) [Record in ScopusGoogle Scholar](#)
5. N.I. Baek, D.S. Kim, Y.H. Lee, J.D. Park, C.B. Lee, S. Il Kim **Ginsenoside Rh4, a genuine dammarane glycoside from Korean red ginseng** Planta Med, 62 (2016), pp. 86-87, [10.1055/s-2006-957816](https://doi.org/10.1055/s-2006-957816) [CrossRefView](#) [Record in ScopusGoogle Scholar](#)
6. D.-W. Jeong, S.-K. Moon, J.-W. Hong, W.-J. Shin, Y.-M. Park, J.H. Jung, *et al.* **Effects of Korean ginseng, Korean red ginseng and fermented Korean red ginseng on cerebral blood flow, cerebrovascular reactivity, systemic blood pressure and pulse rate in humans** J Korean Orient Med, 27 (2016), pp. 38-50 [View Record in ScopusGoogle Scholar](#)
7. K.H. Han **Effect of red ginseng on blood pressure in patients with essential hypertension and white coat hypertension** Am J Chin Med, 26 (1998), pp. 199-209, [10.1142/S0192415X98000257](https://doi.org/10.1142/S0192415X98000257) [View Record in ScopusGoogle Scholar](#)
8. J.H. Heo, S.T. Lee, M.J. Oh, H.J. Park, J.Y. Shim, K. Chu, *et al.* **Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with Korean red ginseng** J Ginseng Res, 35 (2011), pp. 457-461, [10.5142/jgr.2011.35.4.457](https://doi.org/10.5142/jgr.2011.35.4.457) [CrossRefView](#) [Record in ScopusGoogle Scholar](#)
9. J.-H.H. Heo, S.-T.T. Lee, K. Chu, M.J. Oh, H.-J.J. Park, J.-Y.Y. Shim, *et al.* **An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease** Eur J Neurol, 15 (2008), pp. 865-868, [10.1111/j.1468-1331.2008.02157.x](https://doi.org/10.1111/j.1468-1331.2008.02157.x) [CrossRefView](#) [Record in ScopusGoogle Scholar](#)
10. N.-R. Kim, J.-H. Kim, C.-Y. Kim **Effect of Korean red ginseng supplementation on ocular blood flow in patients with glaucoma** J Ginseng Res, 34 (2010), pp. 237-245, [10.5142/jgr.2010.34.3.237](https://doi.org/10.5142/jgr.2010.34.3.237) [CrossRefView](#) [Record in ScopusGoogle Scholar](#)